Lonza reports strong momentum in H1 2021
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
As of 2025, the new Translational Science Center will offer room for more than 500 scientists, who will conduct research in a wide variety of fields ranging from the identification of disease biomarkers to the development of targeted therapies
The first batch will be shipped to the Gamaleya Center for the quality control
Oxygen Park is a concept where a two-layer layout is being used to plant oxygen releasing trees which releases oxygen for 24 hours
Sun Pharma has committed Rs. 100 crores towards these initiatives
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
Subscribe To Our Newsletter & Stay Updated